微信在线咨询
| 产品编号 | 产品名称 | 产品包装 | 产品价格 |
| SM2235-10mM | 升麻素苷(98%, HPLC) | 10mM×0.2ml | 123.00元 |
| SM2235-5mg | 升麻素苷(98%, HPLC) | 5mg | 118.00元 |
| SM2235-25mg | 升麻素苷(98%, HPLC) | 25mg | 490.00元 |
| SM2235-100mg | 升麻素苷(98%, HPLC) | 100mg | 1666.00元 |
化学信息：
| 中文名 | 升麻素苷 |
| 英文名 | Prim-O-glucosylcimifugin |
| 中文别名 | 升麻苷 |
| 英文别名 | Cimifugin 7-glucoside |
| 来源 | 防风Saposhnikovia divaricata (Trucz.) Schischk. |
| 化合物类型 | 色原酮类(Chromones) |
| 化学式 | C22H28O11 |
| 分子量 | 468.45 |
| CAS号 | 80681-45-4 |
| 纯度 | 98%, HPLC |
| 溶剂/溶解度 | DMSO: ≥ 150 mg/ml (320.20 mM) |
| 溶液配制 | 5mg加入1.07ml DMSO，或者每4.68mg加入1ml DMSO，配制成10mM溶液。 |
生物信息
| 产品描述 | Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling. | ||||
| 信号通路 | JAK2/STAT3 | ||||
| 靶点 | COX-2 | iNOS | - | - | - |
| IC50 | - | - | - | - | - |
| 体外研究 | Prim-O-glucosylcimifugin (POG) is the highest content chromone and one of the major active constituents in Radix Saposhnikoviae (RS). Prim-O-glucosylcimifugin exerts anti-inflammatory effects in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 expression by inhibiting JAK2/STAT3 signaling. The cytotoxicity of Prim-O-glucosylcimifugin is measured to LPS-activated Raw 264.7 macrophages. Raw 264.7 macrophages are treated with LPS (1 μg/ml) and increasing concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/ml) for 24 h and cell viability is evaluated by CCK-8 assay. Cell viability is not significantly affected after 24 h and exposure to 15-100 μg/ml Prim-O-glucosylcimifugin as compared with DMSO-treated cells (control). To investigate the anti-inflammatory effect of Prim-O-glucosylcimifugin, whether Prim-O-glucosylcimifugin can affect NO synthesis is examined in LPS-activated RAW 264.7 cells. Macrophages are treated with LPS (1 μg/ml) and various concentrations of Prim-O-glucosylcimifugin (15, 50, and 100 μg/ml) for 24 h. No concentrations are measured in the culture supernatants by Griess reaction. The concentrations of NO in the culture supernatants are markedly increased in response to LPS exposure, and Prim-O-glucosylcimifugin significantly inhibits LPS-induced NO production in a concentration-dependent manner. | ||||
| 体内研究 | Bronchoalveolar lavage fluid (BALF) is collected at 7 h after lipopolysaccharide (LPS) administration and the cytokine levels in BALF are measured by ELISA. The levels of TNF-α, IL-1β and IL-6 in BALF are increased dramatically compared with control group. However, pretreatment with Prime-O-glucosylcimifugin (2.5, 5 or 10 mg/kg) significantly down-regulates the levels of TNF-α, IL-1β and IL-6 in a dose-dependent manner (P<0.05, P<0.01). | ||||
| 临床实验 | N/A | ||||
1. Zhou J, et al. Pharmacogn Mag. 2017,13(51):378-384.
2. Chen N, et al. Int Immunopharmacol. 2013,16(2):139-47.
包装清单：| 产品编号 | 产品名称 | 包装 |
| SM2235-10mM | 升麻素苷(98%, HPLC) | 10mM×0.2ml |
| SM2235-5mg | 升麻素苷(98%, HPLC) | 5mg |
| SM2235-25mg | 升麻素苷(98%, HPLC) | 25mg |
| SM2235-100mg | 升麻素苷(98%, HPLC) | 100mg |
| - | 说明书 | 1份 |
-20℃避光保存，至少一年有效。固体粉末4℃避光保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃避光保存，预计6个月内有效。
注意事项：本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
微信在线咨询
